Cat. No.: HY-N0852

Benzoylpaeoniflorin

Customer Review

Based on 1 Customer Validation

Benzoylpaeoniflorin is an orally active monoterpene glycoside compound. Benzoylpaeoniflorin exerts anti-inflammatory, anti-allergic, psoriasis-improving and sepsis-improving effects by inhibiting signaling pathways such as TNF/NF-κB and MAPK, as well as regulating immune homeostasis. Benzoylpaeoniflorin can be used in research related to immune, allergic and inflammatory diseases.

For research use only. We do not sell to patients.

Purity: 98.47%
CAS No.: 38642-49-8
Formula: C₃₀H₃₂O₁₂
Molecular Weight:584.57

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Benzoylpaeoniflorin Chemical Structure

CAS No.: 38642-49-8

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- In Vitro
- In Vivo
Chemical Information
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

IC₅₀ & Target^[1]

IL-1β

IL-6

All p38 MAPK Isoforms :

All NF-κB Isoforms :

All Interleukin Related Isoforms :

All JNK Isoforms :

All CXCR Isoforms :

In Vitro

Benzoylpaeoniflorin (0-800 μM; 24-72 h) shows no cytotoxicity against human HaCaT keratinocytes at concentrations up to 200 μM and exposure durations up to 72 h, while higher concentrations induce dose- and time-dependent cytotoxicity^[1].
Benzoylpaeoniflorin (200 μM; 0-14 d) inhibits TNF-α-induced proliferation of human HaCaT keratinocytes by arresting cell cycle progression, and a sustained antiproliferative effect is observable within 14 d^[1].
Benzoylpaeoniflorin (200 μM) inhibits TNF-α-induced activation of the NF-κB pathway in human HaCaT keratinocytes, reduces the nuclear translocation of p-p65, and decreases the secretion of downstream proinflammatory cytokines IL-1β, IL-6 and CXCL10^[1].
Benzoylpaeoniflorin (0-10 μM; 9-30 h) inhibits LPS (HY-D1056)-induced mRNA and protein expression of IL-6 and TNF-α in HUVECs and THP-1 macrophages in a time- and dose-dependent manner^[2].
Benzoylpaeoniflorin (0-50 μM; 48 h) exhibits no cytotoxicity towards human umbilical vein endothelial cells (HUVECs) and THP-1 macrophages^[2].
Benzoylpaeoniflorin (2-10 μM; 9-30 h) inhibits LPS-induced iNOS mRNA and protein expression in a time- and dose-dependent manner, as well as NO production in human umbilical vein endothelial cells (HUVECs) induced by LPS + IFN-γ^[2].
Benzoylpaeoniflorin (2-10 μM; 7 h) inhibits the phosphorylation of NF-κB (p65) and mitogen-activated protein kinases (MAPKs, including p38, JNK, ERK) induced by LPS in human umbilical vein endothelial cells (HUVECs) and THP-1 macrophages in a time- and dose-dependent manner^[2].
Benzoylpaeoniflorin (5-100 μM; 24 h) inhibits HDC activity in *Klebsiella pneumoniae* cultures, and incubation at 100 μM for 24 h reduces histamine production by up to 50%^[3].
Benzoylpaeoniflorin (25 h) potently inhibits IgE-mediated mast cell degranulation in DNP-BSA-stimulated RBL-2H3 cells: it exhibits an EC₅₀ of 6.34 μM for inhibiting β-HEX and an EC₅₀ of 18.06 μM for inhibiting HIS, and shows no cytotoxicity at concentrations up to 100 μM^[3].
Benzoylpaeoniflorin (5-100 μM; 25 h) downregulates the production of proinflammatory cytokines IL-3, IL-4, IL-5 and IL-13 in DNP-BSA-stimulated RBL-2H3 cells^[3].
Benzoylpaeoniflorin inhibits the activation of the MAPK signaling pathway in DNP-BSA-stimulated RBL-2H3 cells by reducing the phosphorylation levels of p38, ERK1/2 and JNK proteins^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cytotoxicity Assay^[1]

Cell Line:

Human HaCaT keratinocytes
Concentration:

0, 50, 100, 200, 300, 400, 600, 800 μM
Incubation Time:

24, 48, 72 h
Result:

Showed no significant cytotoxicity at concentrations below 200 μM after 72 h of continuous treatment.
Induced a dose-dependent and time-dependent decrease in cell viability at concentrations exceeding 300 μM.
Reduced cell survival rate to less than 50% after 72 h exposure at concentrations above 400 μM.

ELISA Assay^[3]

Cell Line:

DNP-BSA-stimulated RBL-2H3 cells
Concentration:

5, 25, 100 μM
Incubation Time:

24 h (prior to 1 h DNP-BSA stimulation)
Result:

Markedly downregulated the overproduction of IL-3, IL-4, IL-5, and IL-13 compared to the model group.

In Vivo

Benzoylpaeoniflorin (0.3-0.6% cream; topical administration; once daily; for 7 consecutive days) significantly alleviates imiquimod (HY-B0180)-induced psoriasiform inflammation in female SKH-1 mice by restoring immune homeostasis, reducing keratinocyte proliferation, and inhibiting the TNF-α/NF-κB signaling pathway^[1].
Benzoylpaeoniflorin (0.09-0.44 mg/kg; intravenous injection; single administration concurrent with LPS treatment) dose-dependently reduces the production of inflammatory cytokines in serum and peritoneal fluid of LPS-induced mice, alleviates lung tissue injury in mice with non-lethal sepsis, and improves the survival rate of mice^[2].
Benzoylpaeoniflorin (45-180 mg/kg; p.o.; single administration) dose-dependently inhibits IgE-mediated passive cutaneous anaphylaxis in BALB/c mice^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

SKH-1 hairless mice (female, 6 to 8-week-old)^[1]
Dosage:

0.3% cream; 0.6% cream
Administration:

topical; daily; 7 days
Result:

Improved the clinical symptoms and histological features of skin lesions.
Regulated the proportion of immune cells, restores the balance of Th17/Treg cells, and alleviated inflammatory responses by inhibiting the TNF-α/NF-κB signaling pathway.

Animal Model:

C57BL/6 (male, 8-week-old, 27 ± 0.5 g, LPS-induced non-lethal septic shock model)^[2]
Dosage:

0.09, 0.22, 0.44 mg/kg
Administration:

i.v.; single dose concurrent with LPS administration
Result:

Reduced serum levels of IL-6, TNF-α, IL-1β, CXCL1, and CXCL2, as well as levels of these cytokines in peritoneal fluid.
Significantly reduced histopathological scores of lung tissue (based on inflammatory cell infiltration and lesion area).\nAlleviated LPS-induced lung damage as shown by H&E staining.
Achieved 40% survival rate (8 out of 20 mice) at 0.22 mg/kg.
Achieved 60% survival rate (12 out of 20 mice) at 0.44 mg/kg. Control group had 10% survival rate (2 out of 20 mice).

Animal Model:

C57BL/6 (male, 8-week-old, 27 ± 0.5 g, cecal ligation and puncture (CLP)-induced sepsis model)^[2]
Dosage:

0.09, 0.22, 0.44 mg/kg
Administration:

i.v.; administered post-CLP; repeated every 24 hours (survival study)
Result:

Reduced levels of IL-6, TNF-α, and CXCL1 in peritoneal macrophages collected from CLP-operated mice.
Achieved 45% survival rate (9 out of 20 mice) at 0.22 mg/kg for 96 hours.
Achieved 65% survival rate (13 out of 20 mice) at 0.44 mg/kg for 96 hours.

Animal Model:

BALB/c (5-week-old male)^[3]
Dosage:

45 mg/kg; 90 mg/kg; 180 mg/kg
Administration:

p.o.; single dose
Result:

Reduced Evans blue dye leakage from mouse ears in a dose-dependent manner.
Showed statistically significant decreases in absorbance at 620 nm compared to the model group for all tested doses.

Chemical Information

CAS No. 38642-49-8
Appearance Solid
Molecular Weight 584.57
Formula C₃₀H₃₂O₁₂
Color White to off-white
SMILES

O=C(C1=CC=CC=C1)OCC(C(C2(O)O3)C4)(C3OC5(C2)C)C45OC(C(C(O)C6O)O)OC6COC(C7=CC=CC=C7)=O
Structure Classification
- Terpenoids
- Other Monoterpenes
Initial Source
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (171.07 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.7107 mL

8.5533 mL

17.1066 mL

5 mM

0.3421 mL

1.7107 mL

3.4213 mL

10 mM

0.1711 mL

0.8553 mL

1.7107 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (4.28 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (4.28 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (4.28 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (290 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Wei J, et al. Benzoylpaeoniflorin alleviates psoriasis-like inflammation by modulating immune balance and inhibiting NF-κB signaling pathway. Bioorg Chem. 2025;163:108711. [Content Brief]

[2]. Kim C, et al. Benzoylpaeoniflorin Activates Anti-Inflammatory Mechanisms to Mitigate Sepsis in Cell-Culture and Mouse Sepsis Models. Int J Mol Sci. 2022;23(21):13130. Published 2022 Oct 28. [Content Brief]

[3]. Zhong WC, et al. Anti-anaphylactic potential of benzoylpaeoniflorin through inhibiting HDC and MAPKs from Paeonia lactiflora. Chin J Nat Med. 2021;19(11):825-835. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.7107 mL	8.5533 mL	17.1066 mL	42.7665 mL
	5 mM	0.3421 mL	1.7107 mL	3.4213 mL	8.5533 mL
	10 mM	0.1711 mL	0.8553 mL	1.7107 mL	4.2766 mL
	15 mM	0.1140 mL	0.5702 mL	1.1404 mL	2.8511 mL
	20 mM	0.0855 mL	0.4277 mL	0.8553 mL	2.1383 mL
	25 mM	0.0684 mL	0.3421 mL	0.6843 mL	1.7107 mL
	30 mM	0.0570 mL	0.2851 mL	0.5702 mL	1.4255 mL
	40 mM	0.0428 mL	0.2138 mL	0.4277 mL	1.0692 mL
	50 mM	0.0342 mL	0.1711 mL	0.3421 mL	0.8553 mL
	60 mM	0.0285 mL	0.1426 mL	0.2851 mL	0.7128 mL
	80 mM	0.0214 mL	0.1069 mL	0.2138 mL	0.5346 mL
	100 mM	0.0171 mL	0.0855 mL	0.1711 mL	0.4277 mL

Keywords

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Benzoylpaeoniflorin

Cell Cycle/DNA Damage Compound Library

GPCR/G Protein Compound Library

Immunology/Inflammation Compound Library

Kinase Inhibitor Library

MAPK Compound Library

NF-κB Signaling Compound Library

Stem Cell Signaling Compound Library

Natural Product Library

Small Molecule Immuno-Oncology Compound Library

Anti-Aging Compound Library

Covalent Screening Library

Antioxidant Compound Library

Differentiation Inducing Compound Library

Reprogramming Compound Library

Oxygen Sensing Compound Library

Anti-Cardiovascular Disease Compound Library

Endoplasmic Reticulum Stress Compound Library

Terpenoids Library

Pyroptosis Compound Library

Traditional Chinese Medicine Active Compound Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Neurodegenerative Disease-related Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Transcription Factor-Targeted Library

Anti-Liver Cancer Compound Library

Antidepressant Compound Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Chemokine Compound Library

Cancer Stem Cells Compound Library

Pain-Related Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Cytokine Inhibitors Library

Serine/Threonine Kinase Inhibitor Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Covalent Screening Library Plus

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Anti-Gastric Cancer Compound Library

Anti-Fibrosis Compound Library

Miao Ethnicity Medicine Compound Library

Tibetan Medicine Compound Library

PBCRBS Traditional Chinese Medicine Compound Library

Heat-Clearing and Detoxification Traditional Chinese Medicine Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library

Anti-Rheumatic Arthritis Compound Library

Mass Spectrometry Human Metabolite Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Mongolian Medicine Compound Library

Natural Product Diversity Scaffold Library

Tonifying Traditional Chinese Medicine Monomer Compound Library

Lactylation Compound Library

Mass Spectrometry Natural Product Library

All p38 MAPK Isoforms

All NF-κB Isoforms

All Interleukin Related Isoforms

All JNK Isoforms

All CXCR Isoforms

Biological Activity